Rekrutierende Studie = ; Fortlaufende Studie = ; Förderung durch ein IRDiRC-Mitglied = ; ERN-Mitglied =

Nationale klinische Studie(n)

Multinationale klinische Studie(n)

BELGIEN

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

GENEGRAFT: Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (Orphan drug designation (EU/3/09/630))

European Commission

DG Research - Directorate General for Research

Mehr Details

FRANKREICH

ILE-DE-FRANCE
PARIS

GENEGRAFT: Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (Orphan drug designation (EU/3/09/630))

Hôpital Necker-Enfants Malades

Service de dermatologie

Mehr Details